NCNA Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeP/E ratio0.01
EPS (TTM)$134.490.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$7.7MMicro cap
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 0.26
- P/S (TTM)
- —
- EV/EBITDA
- 0.30
Profitability & growth
- ROE (TTM)
- -231.7%
- Operating margin
- 0.0%
- Revenue growth YoY
- 0.0%
- Dividend yield
- —
- Beta
- 2.18
Last earnings
Nov 13, 2025 · Estimate $-13.00 · Reported $-0.08
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About NuCana PLC
Company profileNuCana plc, a clinical-stage biopharmaceutical company, is dedicated to the development of products for the treatment of cancer. The company is headquartered in Edinburgh, the United Kingdom.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 3 LOCHSIDE WAY, EDINBURGH, UNITED KINGDOM
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$7.7M
Shares outstanding$4.2M
52W high$25.58
52W low$1.33
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent